Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 7,057 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer, Breast Neoplasms Clear all
Completed Phase 2 Interventional Results available

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

NCT00777101
View directory record Official record
Conditions
Advanced Breast Cancer, Breast Cancer
Interventions
Neratinib, Lapatinib, Capecitabine
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
44
States / cities
Tucson, Arizona • Murrieta, California • Orange, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 21, 2026, 10:57 PM EDT
Completed Phase 2 Interventional Results available

DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer

NCT01763931
View directory record Official record
Conditions
Breast Cancer
Interventions
Digoxin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 21, 2026, 10:57 PM EDT
Completed Not applicable Interventional Results available

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

NCT01720602
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
vorinostat, anastrozole, letrozole, exemestane, positron emission tomography, F-18 16 alpha-fluoroestradiol, fludeoxyglucose F 18, laboratory biomarker analysis
Drug · Procedure · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 21, 2026, 10:57 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

NCT03906331
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration
Interventions
Selpercatinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
U.S. locations
34
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Duarte, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 21, 2026, 10:57 PM EDT
Terminated Phase 2 Interventional Results available

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

NCT00679029
View directory record Official record
Conditions
HER2-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
doxorubicin hydrochloride, cyclophosphamide, bevacizumab, paclitaxel, gemcitabine hydrochloride, laboratory biomarker analysis, pegfilgrastim
Drug · Biological · Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 21, 2026, 10:57 PM EDT
Withdrawn No phase listed Observational

Clinical Utility of CTC Test in Medicare-Eligible Metastatic Breast Cancer Patients

NCT02111031
View directory record Official record
Conditions
Metastatic Breast Cancer, Breast Cancer
Interventions
Not listed
Lead sponsor
Janssen Diagnostics, LLC
Industry
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Oct 21, 2026, 10:57 PM EDT
Recruiting Not applicable Interventional

Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss

NCT05484973
View directory record Official record
Conditions
Alopecia, Chemotherapy-induced Alopecia, Hair Loss, Breast Cancer
Interventions
AMMA Portalbe Scalp Cooling System
Device
Lead sponsor
Cooler Heads Care Inc.
Government
Eligibility
21 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Tucson, Arizona • Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 21, 2026, 10:57 PM EDT
Recruiting No phase listed Observational

Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior

NCT01000883
View directory record Official record
Conditions
Breast Cancer
Interventions
biologic sample preservation procedure, laboratory biomarker analysis, biopsy
Other · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2032
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 21, 2026, 10:57 PM EDT
Terminated Phase 1 Interventional

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

NCT01929941
View directory record Official record
Conditions
Solid Tumor, Hodgkin's Lymphoma, NHL (Non-Hodgkin Lymphoma), Pancreatic Cancer, Breast Cancer, UC (Ureter and Urethera), Advanced Cancer, Metastatic Cancer
Interventions
INCB047986, Gemcitabine, nab-paclitaxel
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia • Nashville, Tennessee • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 21, 2026, 10:57 PM EDT
Recruiting Not applicable Interventional

Tier Palliative Care For Patients With Advanced Heart Failure or Cancer

NCT07391956
View directory record Official record
Conditions
Advanced Heart Failure, Advanced Non-Colorectal Gastrointestinal Cancer, Advanced Lung Cancer, Advanced Triple Negative Breast Cancer
Interventions
Tier-Palliative Care, Community Health Worker
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
5
States / cities
Astoria, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 21, 2026, 10:57 PM EDT
Completed Phase 3 Interventional Results available

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

NCT01234337
View directory record Official record
Conditions
Breast Cancer
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo, Capecitabine
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
19
States / cities
Greenbrae, California • Sylmar, California • West Palm Beach, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 21, 2026, 10:57 PM EDT
Completed Not applicable Interventional Results available

Metacognitive Strategy Training in Cancer-related Cognitive Impairment

NCT05505045
View directory record Official record
Conditions
Breast Cancer Female
Interventions
CO-OP Procedures, Attention Control Procedures
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 21, 2026, 10:57 PM EDT
Completed Phase 1 Interventional

Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer

NCT01837095
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
POL6326
Drug
Lead sponsor
Polyphor Ltd.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Kansas City, Kansas • St Louis, Missouri • Lebanon, New Hampshire + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 21, 2026, 10:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

CARE: Cancer Risk Perception and Women of Color

NCT06036875
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • Tucson, Arizona • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 21, 2026, 10:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers

NCT04330716
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Metastatic Prostate Cancer
Interventions
Standard Genetic Counseling, Educational Video
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
6
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Milford, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 21, 2026, 10:57 PM EDT
Completed Not applicable Interventional

Hypnosis to Reduce Aromatase Inhibitor Pain and Improve Adherence

NCT02657993
View directory record Official record
Conditions
Breast Neoplasms, Musculoskeletal Pain
Interventions
Hypnosis, Attention Control
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 21, 2026, 10:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression

NCT00033514
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, erlotinib hydrochloride
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 21, 2026, 10:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer

NCT00100893
View directory record Official record
Conditions
Breast Cancer
Interventions
IH636 grape seed proanthocyanidin extract
Dietary Supplement
Lead sponsor
City of Hope Medical Center
Other
Eligibility
40 Years to 75 Years · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 21, 2026, 10:57 PM EDT
Completed No phase listed Observational

Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment

NCT02695121
View directory record Official record
Conditions
Breast Cancer, Bladder Cancer
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
2,133,575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Wilmington, Delaware • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 21, 2026, 10:57 PM EDT
Completed Phase 1 Interventional Results available

Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases

NCT00838929
View directory record Official record
Conditions
Brain Metastases
Interventions
Vorinostat, Radiation Therapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 21, 2026, 10:57 PM EDT
Not listed Phase 2 Interventional

Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer

NCT00003066
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, estramustine phosphate sodium
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 21, 2026, 10:57 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

ARGONAUT: Stool and Blood Sample Bank for Cancer Patients

NCT04638751
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Pancreas Cancer
Interventions
Immunotherapy, Chemotherapy, CRC surgical resection, Colonoscopy
Drug · Procedure
Lead sponsor
Persephone Biosciences
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
10
States / cities
Orange, California • San Diego, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 21, 2026, 10:57 PM EDT
Completed Not applicable Interventional Results available

A Mind-Body Intervention for Hot Flash Management

NCT03572153
View directory record Official record
Conditions
Hot Flashes, Postmenopausal Symptoms, Breast Cancer
Interventions
Self-Administered Hypnosis, Self-Administered White Noise Hypnosis
Behavioral
Lead sponsor
Baylor University
Other
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Ann Arbor, Michigan • Waco, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 21, 2026, 10:57 PM EDT
Completed Phase 2 Interventional Results available

Treatment With Pazopanib for Neoadjuvant Breast Cancer

NCT00849472
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
doxorubicin + cyclophosphamide, paclitaxel + pazopanib, surgery, pazopanib monotherapy
Drug · Procedure
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
137
States / cities
Decatur, Alabama • Huntsville, Alabama • Antioch, California + 97 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 21, 2026, 10:57 PM EDT